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ADRs included seriousness of reaction (75.8%), unusual reaction (63.6%), reaction 
to a new product (66.6%) and confidence in the diagnosis of ADR (31.5%). Similarly, 
the discouraging factors are uncertain association (65.7%), awareness (57.6%), and 
concern about legal liability (51.4%). ConClusions: It is observed that awareness 
of ADRs program need special attention with some concrete steps should be taken 
for the improvement of ADRs system in Pakistan. Continuing medical education, 
training and integration of ADRs reporting into the clinical activities would defi-
nitely improve the patient outcome.
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objeCtives: This study assessed the quality of life associated with erectile dysfunc-
tion (ED) among the U.S. adult population both among diagnosed ED sufferers and 
non-sufferers. Methods: A representative (U.S.) sample of 1,000 adults (502 males, 
498 females) completed an online survey about their own (for men) or partner’s (for 
women in a heterosexual relationship) overall and erectile function health states 
and quality of life. Health states utilities were measured using both SG and VAS 
questions (counterbalanced order). Results: 11.3% of males report having been 
diagnosed with ED and 6.4% of females report that their male partner has been 
diagnosed. Overall, the SG and VAS measures yield very similar but not identical 
utility estimates for the ED health state. The mean utility estimates across all eligible 
respondents are 0.41 (0-1 scale) for the SG and 0.44 for the VAS. Looking just at SG, 
males have lower utility on average (0.37) for the ED health state than do females for 
their partner’s ED health state and there was no difference between males who are 
healthy and those diagnosed with ED. Women whose partners are healthy express 
lower utility for the ED health state (described as “significant difficulty in achieving 
an erection/penis gets hard but not hard enough for penetration”) than women with 
a partner diagnosed with ED. Younger respondents also have lower utility for the ED 
state than older respondents, and for the VAS the utility function across 5 levels of 
ED is linear. ConClusions: The fact that males who have not been diagnosed with 
ED have the same utility for the ED health state as those who have been diagnosed 
indicates that otherwise healthy males accurately anticipate quality of life decline 
associated with ED. Females with a diagnosed partner seem more willing to accept 
living with that partner’s ED health state.
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objeCtives: The accuracy of clinical trial data can be jeopardized if the trans-
lations used in the study are not regionally appropriate, particularly if the COAs 
(Clinical Outcomes Assessments) record direct feedback from patients whose first 
language is not English. Ensuring regional sensitivity in translations can be diffi-
cult in countries like the United States, where four major dialect groups dominate 
the Spanish influence. The purpose of this poster is to review best practices for 
conducting linguistic validation for US-based sites to ensure the most appropri-
ate Spanish language is used. Methods: Past studies that required US Spanish 
were reviewed to analyze specific selections and locations of Spanish-speaking 
patients. Consideration was given to studies incorporating multiple site locations 
around the country, as well as to studies targeting a specific region. Results: US 
Spanish translations yielded the best results when site location was communicated 
to the linguistic validation provider. When this information is not available at project 
commencement, it is necessary to consider the array of national backgrounds and 
subsequent cultural correlations that are present throughout the US when select-
ing translators and cognitive interviewing respondents. When site locations were 
throughout the US, the most inclusive and universal US Spanish was achieved with 
the following cognitive debriefing recruitment formula for a 5 respondent inter-
view: 2 Mexican respondents, 1 South American respondent, 1 Central American 
respondent, and 1 Caribbean respondent. If site locations are being concentrated 
in one area, selecting a team that represents the largest population in that region 
is ideal. ConClusions: Determining US site location prior to translation is recom-
mended to ensure a more comprehensive translation that is tailored toward the 
target population, therefore yielding the most accurate responses. If sites have not 
been confirmed within the US, a recruitment formula developed to account for 
major Spanish populations in the US is recommended.
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objeCtives: The objective of this pilot study was to investigate the associations 
among perceived stress, acculturative stress, coping mechanisms, and health-
related quality-of-life of graduate students. Methods: A cross-sectional, self-
administered questionnaire was distributed to UT-ISPOR graduate students. 
Participants were recruited using an email cover letter sent through the UT-ISPOR 
mailing list. Willing participants were asked to complete the survey (either web-
based or paper-pencil method). The questionnaire consisted of five sections: 1) 
SF-12 Health Survey (mental component summary [MCS], and physical component 
summary [PCS]); In the general population, these scores have a mean of 50 and 
a standard deviation of 10, with higher scores correlating with better HRQoL; 2) 
Graduate Stress Inventory-Revised (GSI-R) Scale (higher scores = higher stress) ; 
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objeCtives: Previous reviews of patient-reported outcome (PRO) label claims did 
not distinguish products with orphan designation. Prior analyses suggest less evi-
dence is required for orphan drug approvals compared to non-orphan drugs. This 
study aimed to identify orphan drug products approved by the US Food and Drug 
Administration (FDA) between 2006 and 2013, prevalence of PRO label claims for 
these products, and evidence supporting PRO claim approval. Methods: Using the 
Drugs@FDA database, new molecular entities and biologic licensed agents approved 
between January 2006 and September 2013 with orphan review classification were 
identified, with subsequent label review. For products with PRO label claims, medical 
and summary review sections from FDA drug approval packages were reviewed to 
identify reviewing division, indication, review designation (priority, standard), PRO 
endpoint status, PRO measure type, number of phase 3 trials supporting claims, and 
PRO-related SEALD comments. Descriptive data were recorded in Microsoft Excel; 
frequency of measured characteristics was analyzed. Results: Of 43 orphan prod-
ucts identified, 5 (12%) included PRO label claims. Five orphan products achieved 
7 PRO claims. Priority and standard review prevalence were similar (44% vs. 40%, 
respectively) for orphan products; the majority (4 of 5) of products with PRO claims 
were priority review. A slight majority (60%; 3 of 5 orphan products) included PRO 
claims supported by ≤ 1 phase 3 trial. Signs/symptoms measures and secondary 
PRO endpoints were most common (57% each). FDA reviewing division varied. One 
product received PRO-related SEALD comments. ConClusions: For the time period 
evaluated, orphan products rarely included a PRO label claim. These claims may 
not be needed for orphan product differentiation to the degree that they are for 
non-orphan products. PRO claims achieved for orphan products appear to require 
less supporting evidence for approval than non-orphan products, consistent with 
orphan drug approval expectations but in contrast to FDA PRO guidance criteria.
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objeCtives: Anabolic prohormones, similar to anabolic-androgenic steroids, are 
sold as dietary supplements in the United States. There is very little known about 
the health outcomes associated with exposure to prohormones. The objective of 
this study was to assess health outcomes and user perceptions about health out-
comes associated with prohormone use. Methods: A self-administered survey was 
developed and deployed via two e-forums dedicated to prohormone use. Questions 
included information about health outcomes, beliefs about the commonality of 
side effects in users, and prohormone use characteristics including number of sub-
stances taken, number of cycles completed in a year, and taking the recommended 
or excess dosage. Outcomes were correlated with beliefs. Logistic regressions were 
used to measure the association between dose categories and self-reported out-
comes. A multiple risk factor analysis looked at the association between higher than 
average number of self-reported outcomes and several combined risk indicators. 
Combined risk indicators comprised of taking above recommended dose merged 
in combination with highest number of substances per cycle, highest number of 
cycles per year and having also taken AAS in the last year, respectively. Results: 
Eighteen self-reported outcomes were generated from 65 responders. Users reported 
an average of 2.49 (SD-0.60) outcomes in their last prohormone cycle. Correlations 
showed those who experienced no outcomes believe adverse events are uncom-
mon (R= 0.26, P= 0.04). Conversely, those who experienced the highest number of 
outcomes are not correlated with the belief that outcomes are common (R= 0.17.
P= 0.16). No outcome was significantly associated with taking more than the rec-
ommended dose. Multiple risks showed no significant association with an above 
average number of reported outcomes. cOnclusIOns: This study is a pilot into an 
understudied population. Despite having a small sample, this study is the first of 
its kind in compiling self-reported outcomes in prohormone users.
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objeCtives: ADRs are known to be a major cause of morbidity and mortality. 
However, only a very little proportion is reported. ADRs contribute to the incidence 
of adverse events, resulting in increased health care costs. Methods: The first 
part of this project was to review the ADRs reporting system in Pakistani hospitals, 
to determine the factors contributing to the ADR reporting rate and benchmark 
with developed countries. Data was collected by self-administered questionnaire. 
24 (80%) hospitals have no proper ADRs system; five (16.7%) hospitals are targeting 
few of the drugs for ADRs reporting while only one (3.3%) hospital has a proper ADRs 
policy including online reporting system as well. Only seven (23.3%) hospitals have 
a policy of ADRs reporting. The next part of the project was a survey of 84 doctors 
and 52 Pharmacists selected from Lahore, Pakistan to evaluate their involvement, 
understanding and reasons for reporting ADRs. A self-administered questionnaire 
was used to collect the data. Results: Response rate obtained for the doctors 
was (39.3% n= 33) and (67.3% n= 35) for hospital pharmacists. Thirty three (39.3%) 
doctors and thirty four (65.4%) pharmacists knew how to report ADRs within the 
hospital while 9 (10.7%) doctors and 13 (25%) Pharmacists knew about the ADRs 
reporting to Ministry of Health. Factors that would encourage respondents to report 
